

KATHRYN F. McGONIGLE, M.D.

Women's Cancer Care of Seattle

Gynecologic Oncology
1560 North 115th St.
Medical Office Building Suite 101
Seattle, WA 98133

Telephone: 206-368-6806
FAX: 206-368-6808

EDUCATION

Fellowship	Gynecologic Oncology 1991-1993	University of California Los Angeles, California
Residency	Obstetrics and Gynecology 1985-1988	University of California San Francisco, California
Internship	Obstetrics and Gynecology 1984-1985	University of California San Francisco, California
Medical	M.D., Cum Laude 1980-1984	St. Louis University School St. Louis, Missouri
Graduate	M.P.H. Environmental Health Sciences 1978-1979	University of California Berkeley, California
Undergraduate	B.S. Chemical Engineering 1974-1978	University of Notre Dame Notre Dame, Indiana

MEDICAL LICENSURE

Washington	MD00040252	2001-current
California	#G56552	1985-2001
Maryland	#D37385	1988-1991

BOARD CERTIFICATION

National Boards Part I, II, III	1982-1985
General Board Certification OB/Gyn No. 88-4774-050554	1988
General Board OB/Gyn oral examination	1990
Gynecologic Oncology written certifying examination	1994
Gynecologic Oncology oral examination	1997
General OB/Gyn and Gynecologic Oncology recertification	2000-2010

ACADEMIC APPOINTMENTS

2001-Present	Clinical Assistant Professor Gynecologic Oncology Department of Obstetrics and Gynecology University of Washington Seattle, WA
1997-2001	Assistant Professor Gynecologic Oncology Department of Obstetrics and Gynecology UCLA School of Medicine Los Angeles, California
1994-1997	Assistant Adjunct Professor Department of Obstetrics and Gynecology University of California, Irvine Irvine, California
1993-1997	Staff Surgeon Department of Gynecology City of Hope National Medical Center Duarte, California
1991-1993	Clinical Instructor Department of Obstetrics and Gynecology UCLA Medical School Los Angeles, California
1988-1991	Clinical Instructor Department of Obstetrics and Gynecology Johns Hopkins University School of Medicine Francis Scott Key Medical Center Baltimore, Maryland

PROFESSIONAL ACTIVITY

Awards and Honors

2001	Teaching award of appreciation: UCLA Gynecologic Oncology Fellows (1997-2001)
1999	Teaching award of appreciation: UCLA OB/GYN Resident Class
1999	WAGO James Nolan Award: best presentation by WAGO member
1991	American Cancer Society Clinical Oncology Fellowship Award
1984	American Medical Women's Association - Jane Glasgow Award
1984	Florent Franks Award in Physiology
1984	Randal Meglitsch Award in Obstetrics and Gynecology
1983	AOA Medical Society
1978	Tau Beta Pi Engineering Honor Society, Dean's Honor List

Contracts, Grants and Research Awards

2005-current	Principal Investigator: Phase II Study of Weekly Topotecan with Bevacizumab in Platinum Resistant Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers: Supported by Glaxo Smith Kline (drug and financial), and Genentech (drug only)
2005-2007	Gynecologic Oncology Group Virginia Mason Medical Center Institutional Principal Investigator
1994-1997	Tamoxifen and Uterine Effects: A Prospective Study City of Hope Breast Cancer Initiative Seed Grant Kathryn F. McGonigle, M.D., P.I. \$34,000
1994-1997	Gynecologic Oncology Group City of Hope Institutional Principal Investigator
1990-1995	Hormone replacement therapy in postmenopausal women ages 65 and older: clinical side effects and efficacy. Francis Scott Key Institutional Grant CERT Chesapeake Education Research Training Kathryn F. McGonigle, M.D., Co-PI \$5,000.00

Service to Professional Societies:

2004-2005	Seattle Gynecologic Society, Program Chair
1996-2000	Gynecologic Oncology Group, Endometrial Committee
1994-2000	Southwest Oncology Group (SWOG) Gynecologic Cancer Committee
1994-1996	Consultant, National Surgical Adjuvant Breast and Bowel Project (NSABP) for Endometrial Screening for Breast Cancer Prevention Trial (BCPT)

Presentations

Robotic Surgery: Present and Future Applications in Gynecologic Oncology. Group Health Associates, Seattle, WA, May, 2007.

Pseudomyxoma Peritonei: Pathology and Management of the Jelly Belly. Grand Rounds, Virginia Mason Medical Center, Seattle, WA, September 29, 2006.

Cervical Cancer Cytology and Screening. Cancer Screening and Early Detection 2004: What the Primary Care Provider Needs to Know. Virginia Mason Medical Center, Seattle, WA, June 22, 2004.

Cervical Cancer Screening and the impact of HPV testing. Grand Rounds, Virginia Mason Medical Center, Seattle, WA, April 9, 2004.

Management of Abnormal Pap Smears-What's New?. General Medical Grand Rounds, St. Francis Hospital, Federal Way, WA, January 23, 2004.

Surgical Management of Ovarian Cancer, Martha Rivkin Group, Swedish Medical Center, Seattle, WA, November 4, 2003

Management of the Abnormal Pap Smear and Bethesda 2001. Olympic Memorial Hospital. Port Angeles, WA, November 20, 2002.

The Hereditary Risk of Ovarian Cancer. Grand Rounds, Virginia Mason Medical Center, Seattle, WA, September 20, 2002.

The Hereditary Risk of Ovarian Cancer. Seattle GYN Society. 2002 Fall Assembly Seattle, WA, September 27, 2002.

Prevention and Screening of Gynecologic Malignancies, Cancer Screening and Detection-An Update for Primary Care Course. Virginia Mason Medical Center, Seattle, WA, April 19, 2002.

Gestational Trophoblastic Neoplasia. Ventura County Medical Center, OB/GYN Grand Rounds, Ventura, California, December 6, 2000.

Cervical Cancer: Management in 21st Century University of California, Los Angeles. OB/GYN Grand Rounds, Los Angeles, California, September, 2000.

Cervical Cancer: Management in 21st Century. Ventura County Medical Center, OB/GYN Grand Rounds, Ventura, California, December, 1999.

Abnormal Uterine Bleeding- New Approaches. Controversies in Women's Health Symposium. Disneyland Hotel, Anaheim, California, July 23, 1999

Prevention of Gynecologic Malignancies. Course - The Biological and Social Basis of Prevention. School of Public Health, University of California Los Angeles, April 13, 1999.

Gynecologic Effects of Tamoxifen. Kern County Medical Center. OB/GYN Grand Rounds, Bakersfield, California, April 9, 1999.

Hormone Replacement Therapy and Breast Cancer. Course - M294 Molecular Basis of Cancer, University of California, Los Angeles, May 1, 1998.

Gynecologic Effects of Tamoxifen. University of California, Los Angeles. OB/GYN Grand Rounds, Los Angeles, California, April 22, 1998.

Prevention of Gynecologic Malignancies. Course - The Biological and Social Basis of Prevention. School of Public Health, University of California Los Angeles, April 16, 1998.

Serum Tumor Markers in Epithelial Ovarian Cancer. American Association for Clinical Chemistry, Anaheim, California, March 11, 1998.

Gynecologic Effects of Tamoxifen. White Memorial Medical Center, OB/GYN Grand Rounds, Los Angeles, California, January 7, 1998.

Gynecologic Effects of Tamoxifen. Ventura County Medical Center, OB/GYN Grand Rounds, Ventura, California, December 17, 1997.

Gynecologic Effects of Tamoxifen. Olive View - UCLA Medical Center, OB/GYN Grand Rounds, Sylmar, California, December 12, 1997.

The Gynecologic Effects of Tamoxifen. Kaiser Permanente Hospital OB/GYN Grand Rounds, Panorama City, California, May 8, 1997

The Uterine Effects of Tamoxifen: Prospective Study Update. Breast Cancer Seed Grant Lecture Series. City of Hope National Medical Center, Duarte, California, May 5, 1997

Ovulation Induction and Ovarian Cancer. Women's Health Symposium, Cancun, Mexico, December 8, 1996

Hormone Replacement Therapy in Women with a History of Breast Cancer. Women's Health Symposium, Cancun, Mexico, December 7, 1996

The Gynecologic Effects of Tamoxifen. Women's Health Symposium, Cancun, Mexico, December 6, 1996.

Ovulation Induction and Ovarian Cancer. UCI OB/GYN Grand Rounds, Orange, California, November 15, 1996

Hormone Replacement Therapy in Breast Cancer Patients. City of Hope National Medical Center Medical Oncology Lecture Series, Duarte, California, July 24, 1996

The Uterine Effects of Tamoxifen: Prospective Study Update. Breast Cancer Retreat, Santa Monica, California, July 13, 1996

Critical Assessment of the Risks and Benefits of Estrogen Replacement Therapy in Patients with Breast Cancer or Gynecological Malignancies. City of Hope National Medical Center, Radiation Oncology Lecture Series, Duarte, California, November 3, 1995

Management of Trophoblastic Disease. UCI OB/GYN Review Course, Costa Mesa, California, October 1995

The Gynecologic Effects of Tamoxifen. City of Hope National Medical Center, Medical Oncology Lecture Series, Duarte, California, October 25, 1995

The Gynecologic Effects of Tamoxifen. UCI OB/GYN Grand Rounds, Orange, California, September 1995

The Gynecologic Effects of Tamoxifen. Kaiser Permanente Hospital OB/GYN Grand Rounds, Santa Clara, California, April 1995

The Gynecologic Effects of Tamoxifen. Kaiser Permanente Hospital OB/GYN Grand Rounds, Baldwin Park, California, March 1995

The Gynecologic Effects of Tamoxifen. University of California OB/GYN Grand Rounds, Los Angeles, California, April 28, 1995

Management of Trophoblastic Disease. UCI OB/GYN Review Course, Costa Mesa, California, November 1994

The Gynecologic Effects of Tamoxifen. Kaiser Permanente Hospital OB/GYN Grand Rounds, Bellflower, California, November 1994

The Gynecologic Effects of Tamoxifen. White Memorial Hospital OB/GYN Grand Rounds, Los Angeles, California, November 1994

Diagnosis of Cancer of the Corpus and Precursors. UCLA OB/GYN Review Course, Los Angeles, California, November 1994

Applied Surgical Anatomy. UCI OB/GYN Lecture Series, Orange, California, October 1994

The Gynecologic Effects of Tamoxifen. University of Utah OB/GYN Grand Rounds, Salt Lake City, Utah, October 1994

Endometrial Cancer. NSABP, Breast Cancer Prevention Trial meeting, Pittsburgh, Pennsylvania, October 1994

Vulvar Cancer. White Memorial Hospital OB/GYN Grand Rounds, Los Angeles, California, May 1994

Endometrial Cancer. City of Hope National Medical Center, Medical Oncology Lecture Series, November 1993

Pelvic Anatomy. White Memorial Hospital OB/GYN Grand Rounds, Los Angeles, California, November 1993

Management of Trophoblastic Disease. UCI OB/GYN Review Course, Costa Mesa, California, November 1993

Breast Cancer and Oral Contraceptives. Cedars-Sinai Medical Center OB/GYN Grand Rounds, Los Angeles, California, July 1992

Breast Cancer and Oral Contraceptives. Johns Hopkins OB/GYN Grand Rounds, Baltimore, Maryland, March 1991

Membership in Professional Organization

1990 – Present	American College of Obstetricians and Gynecologists (ACOG) - Fellow
1991 – 1993	American Cancer Society (ACS)
1992 – 1998	American College of Surgeons (ACS) - Associate Member
1993 – Present	Society of Gynecologic Oncologists (SGO)
1993 – Present	Gynecologic Oncology Group
1993 – 2000	Los Angeles Obstetrical and Gynecological Society
1994 – 2000	Southwest Oncology Group (SWOG) - Gynecologic Cancer Committee
1995 – 1997	Society of Surgical Oncology (SSO)
1995 – 1997	Los Angeles Surgical Society
1998 – Present	Western Association of Gynecologic Oncologists (WAGO)
2001 – Present	Seattle GYN Society
2001 – Present	American Medical Association
2001 – Present	King County Medical Society
2001 – Present	Washington State Medical Association
2001 – Present	Puget Sound Oncology Consortium

UNIVERSITY AND PUBLIC SERVICE

Hospital

Virginia Mason Medical Center Seattle, WA

2001- Current Gynecologic Tumor Committee
2002- 2007 Gynecologic M&M Committee (Chair)

UCLA Medical Center Los Angeles, California

1999 – 2001 Internal Scientific Peer Review Committee (ISPRC)
1997 – 2001 Quality Assurance Committee
1998 – 2001 Cancer Committee

City of Hope National Medical Center Duarte, California

1993 – 1997 Continuing Medical Education Committee
1993 – 1997 Institutional Review Board
1995 – 1997 Nutrition Support Committee

Francis Scott Key Medical Center Baltimore, Maryland

1988 – 1991 Patient Care Committee
1988 – 1991 Credentialing Committee
1989 – 1991 Laser Safety Committee
1990 – 1991 Endoscopic Surgical Committee

Journal Reviewer

1998 – Present Reviewer for *Gynecologic Oncology*
1998 – Present Reviewer for *Fertility and Sterility*
1995 – Present Reviewer for *Gynecologic Techniques*
1995 – Present Reviewer for *Obstetrics and Gynecology*
2006 – Present Reviewer for *International Journal Gynecological Cancer*

Community

Prevention of Gynecologic Malignancies. AIDS Project LA. Los Angeles, CA, November 20, 1998.

Gynecologic Effects of Breast Cancer Therapies: Breast Cancer Support Group, UCLA, Los Angeles, California, September 22, 1998.

Women and Cancer: An Update on Ovarian Cancer: Santa Monica-UCLA Women's Lecture Series, Santa Monica, CA, May 18, 1998.

Gynecologic Effects of High Dose Chemotherapy: Breast Cancer Support Group, Sherman Oaks, California, November 20, 1996.

Tamoxifen Effect: Breast Cancer Support Group, UCLA, Los Angeles, California, 1994.

Gynecologic Effects of DES: Los Angeles DES Daughters, Los Angeles, California, 1992.

PUBLICATIONS

Book Chapters

1. **McGonigle KF**, Huggins GR. Oral contraceptives and breast disease. In: Stoll BA, ed. Approaches to Breast Cancer Prevention. Netherlands: Kluwer Academic Publishers, 1991.
2. **McGonigle KF**, Lagasse LD, Karlan BY. Ovarian, uterine and cervical cancer in the elderly woman. In: Kaider FE, ed. Clinics in Geriatric Medicine. Philadelphia: WB Saunders Co., 1993
3. Huggins GR, **McGonigle KF**, Zucker P. Oral contraceptive use and neoplasia. In: Wallach EE, Zacur HA, eds. Reproductive Medicine and Surgery. St. Louis: Mosby-Year Book, 1995.
4. **McGonigle KF**, Huggins GR. Choosing hormonal contraception. In: Stoll BA, ed. Reducing Breast Cancer Risk in Women. Netherlands: Kluwer Academic Publishers, 1995.
5. **McGonigle KF**. Radiation associated bowel complications. In: Vasilev SA, ed. Perioperative Care in Gynecologic Oncology: Evidence-Based Management. John Wiley and Sons, 2000.
6. **McGonigle KF**, Lagasse LD. Perioperative care in the management of vulvar cancer. In: Vasilev SA, ed. Perioperative care in gynecologic oncology: Evidence-Based Management. John Wiley and Sons, 2000.
7. Kupferman S, **McGonigle KF**. Evaluation of Adnexal Masses & Screening for Ovarian Cancer. In: Lemcke D, Pattison J, Marshal LA,

Cowley DS, eds. Current Care of Women: Diagnosis and Treatment. Lange Medical Books, McGraw-Hill, New York, 2004.

BOOK REVIEWS

McGonigle KF Reviewed book entitled, "Endometrial Carcinoma and Precursors: Diagnosis and Treatment." Mencaglia L, Valle RF and Lurain J (eds) – ISIS Medical Media Limited – Oxford, England – Oncology 14(1):116.

Journal Articles, Peer Reviewed

1. Golbus MS, **McGonigle KF**, Goldberg JD, Filly RA, Callen PW, Anderson RL. Fetal tissue sampling: the San Francisco experiences of 190 pregnancies. West J Med 150:423, 1989.
2. **McGonigle KF**, Huggins GR. Oral contraceptives and breast disease. Fertil Steril 56:799, 1991.
3. **McGonigle KF**, Dudzinski MR. Case Report: endometrial carcinoma of the ovary presenting with an enlarged inguinal lymph node without evidence of abdominal carcinomatosis. Gynecol Oncol 45:225, 1992.
4. **McGonigle KF**, Karlan BY, Barbuto DA, Leuchter RS, Lagasse LD, Judd HL. Development of endometrial cancer in women on estrogen and progesterin hormone replacement therapy. Gynecol Oncol 55:126, 1994.
5. Vasilev SA, **McGonigle KF**, Spencer-Smith L. Intestinal peritoneal sling as an adjuvant to radical pelvic surgery and/or adjuvant irradiation. J Am Coll Surg 180:568, 1994.
6. Vasilev SA, **McGonigle KF**. Extraperitoneal laparoscopic para-aortic lymph node dissection in a pig model: development of a technique. J Lapar Surg 5(2):85, 1995.
7. **McGonigle KF**, Lavey RH, Juillard GJF, Berek JS: Complications of radiation therapy for gynecologic malignancies in elderly women. Int J Gyn Cancer 6:149, 1996.
8. **McGonigle KF**, Lantry SA, Odom-Maryon TL, Chai Akiko, Vasilev SA, Simpson JF: Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. Cancer Letters 101:59, 1996.

9. Vasilev SA, **McGonigle KF**: Extraperitoneal laparoscopic para-aortic lymph node dissection. *Gynecol Oncol* 61:315, 1996.
10. McMeekin DS, **McGonigle KF**, Vasilev SA. Cervical cancer prevention: Toward cost-effective screening. *Medscape Women's Health* 2(12), 1997.
11. **McGonigle KF**, Shaw S, Vasilev SA, Odom-Maryon TL, Roy S, Simpson JF. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. *Am J Obstet Gynecol* 178(6):1145-50, 1998.
12. Morgan RJ, Newman EM, Doroshov JH, **McGonigle KF**, Margolin K, Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B, Yen Y, Klevecz R. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetics analysis. *Cancer Res.* 1998;58:2793-800.
13. Gil B, Simpson JF, Somlo G, **McGonigle KF**, Wilczynski SP. Effects of tamoxifen on the cytology of the uterine cervix in breast cancer patients. *Diagn Cytopath* 19:417-422, 1998.
14. Monk BJ, Fowler JM, Burger RA, **McGonigle KF**, Eddy GI, Montz FJ. Expanded polytetrafluoroethylene is an effective barrier in preventing pelvic adhesions after radical surgery for ovarian carcinoma. *Int J Gynecol Oncol* 8:403-408, 1998
15. **McGonigle KF**, Vasilev SA, Odom-Maryon TL, Simpson JF. Ovarian histopathology in breast cancer patients receiving tamoxifen. *Gynecol Oncol* 73:402-406, 1999.
16. Brewster WR, DiSaia PJ, Grosen EA, **McGonigle KF**, Kuykendall JL, Creasman WT. An experience with estrogen replacement therapy in breast cancer survivors. *Int J Fertil* 44(4):186-192, 1999.
17. Morgan RJ, Doroshov JH, Leong L, Schriber J, Shibata S, Forman S, Hamasaki V, Margolin K, Somlo G, Alvarnas J, McNamara M, Longmate J, Raschko J, Chow W, Vasilev S, **McGonigle K**, Yen Y. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. *Bone Marrow Transplant* 28(9):859-63, 2001.

18. O'Connel JT, Tomlinson JS, Roberts AA, **McGonigle KF**, Barsky SH. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells. *Am J Pathol* 161(2):551-64, 2002.
19. Elkas JC, Holschneider CH, Katz B, Li AJ, Pharm RL **McGonigle KF**, Berek JS. The use of continuous infusion topotecan in persistent and recurrent ovarian cancer. *Int J. Gynecol CA* 13:138-141, 2003.
20. Muntz H, Goff B, **McGonigle KF**, Isaacson C. The significance of psommoma bodies in screening cervical cytologic smears. *Am J Obset Gynecol* 188:1609-14,2003.
21. Morgan RJ, Synold T, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, **McGonigle KF**, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshov JH. Phase II trials of carboplatin and infusional cyclosporine with or without alpha-interferon in recurrent ovarian, fallopian tube or primary peritoneal cancer. *Cancer Chemother Pharmacol* 54:283-9, 2004.
22. Begley, JS, Kupferman, SP, Kuznetsov DD, Kobashi KC, Govier FE, **McGonigle KF**, Muntz HG. Incidence and management of sacrocolpopexy mesh erosions. *Am J Obstet Gynecol* 192:1956-62,2005.
23. Govier FE, Kobashi KC, Kozlowski PM, Kuznetsov DD, Begley SJ, **McGonigle KM**, Muntz HG. High complication rate identified in sacrocolpopexy patients attributed to silicone mesh. *Urology* 65:1099-1103,2005.
24. Ellenhorn JDI, Smith DD, Schwartz RE, Kawachi MH, Wilson TG, **McGonigle KF**, Wagman LD, Paz IB. Paint-only is equivalent to scrub-and-paint in preoperative preparation of abdominal surgery sites. *J Am Coll Surg* 201:737-741,2005.
25. **McGonigle KF**, Smith DD, Marx HF, Morgan RJ, Vasilev SA, Roy S, Morgan RJ, Wong PT, Simpson JF, Wilczynski SP. Uterine effects of tamoxifen: a prospective study. *Int J Gynecol Cancer*. 16 (2): 814-820, 2006.
26. Morgan RJ, Synold TV, Gandara D, Muggia F, Scudder S, Reed R, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, **McGonigle K**, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshov JH. Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. *Int J Gynecol Cancer*. 17:373-378, 2007.

Journal Articles, Other (includes non-peer reviewed)

1. **McGonigle KF**, Huggins GR. Tubal sterilization: epidemiology of regret. *Contemp Obstet Gynecol* 35:15, 1990.
2. **McGonigle KF**, Berek JS. Early-stage squamous cell and adenocarcinoma of the cervix. *Curr Opin Obstet Gynecol* 4:109, 1992.
3. **McGonigle KF**. How oral contraceptives affect breast disease. *Contemp Obstet Gynecol* 37:156, 1992.
4. **McGonigle KF**. How progestins reduce endometrial cancer risk in ERT users. *Contemp Obstet Gynecol* 42:96-108, 1997.
5. Yamada SD, **McGonigle KF**. Cancer of the endometrium and corpus uteri. *Curr Opin Obstet Gynecol* 10:57-60, 1998.
6. Chen LM, **McGonigle KF**, Berek JS. Endometrial Cancer: Recent Developments in Evaluation and Treatment. *Oncology* 13:1665-1682, 1999

Letters to the Editor

1. **McGonigle KF**, Shaw SL, Vasilev SA, Odom-Maryon T, Roy S, Simpson JF. Response to Letter to the Editor titled Ultrasonographic evaluation of endometrial pathologies in postmenopausal breast cancer patients with tamoxifen treatment) Response was to this article: *Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy*. *Am J Obstet Gynecol* 178(6)1145-50, 1998.

IMAGES

1. Barsky SH, McGonigle K. Images in clinical medicine. Pseudomyxoma peritonei. *N Engl J Med* 350: e13, 2004.

Abstracts and Posters

1. Bellantoni MF, Harman SM, Vittone JL, Bryant L, Bass KM, Cotrell E, Copley CJ, **McGonigle KF**, Blackman MR. Android body habitus is associated with decreased growth hormone secretion in postmenopausal women. Oral presentation. The American Federation for Clinical Research, Baltimore, Maryland, May 1992.

2. **McGonigle KF**, Karlan BY, Barbuto DA, Chen D, Lagasse LD, Judd HL. Endometrial cancer developing in women on combination estrogen and progestin therapy - a retrospective analysis. Post presentation. American College of Obstetricians and Gynecologists (ACOG) Annual Meeting, Washington, DC, May 1993.
3. **McGonigle KF**, Karlan BY, Barbuto DA, Leuchter RS, Lagasse LD, Judd HL. Development of endometrial cancer on estrogen and progestin hormone replacement therapy. Oral presentation. Western Association of Gynecologic Oncologists (WAGO) Santa Monica, California, May 1993.
4. Bellantoni M, Vittone J, Bass K, **McGonigle KF**, Davidoff A, Haszard S, Harman SM, Tobin J, Blackman M. Low dose daily estrogen and progestin therapy in older postmenopausal women. Gerontological Society of America 47th Annual Society Meeting, Atlanta, Georgia, November 1994.
5. **McGonigle KF**, Simpson JF, Gill BL, Maryon TL, Wilzcynski SP, Vasilev SA. Uterine pathology in breast cancer patients on Tamoxifen. American Society of Clinical Oncology (ASCO), Dallas, Texas, May 1994.
6. Vasilev SA, **McGonigle KF**. Extraperitoneal laparoscopic para-aortic lymph node dissection: development of a technique. Society of Gynecologic Oncology (SGO), San Francisco, California, February 1995.
7. Morgan R, Kevecz R, Doroshow JH, Newman E, Carroll M, Coluzzi P, Leong L, Shibata S, Chow W, Vsilev S, **McGonigle KF**. Effects of intravenous (IV) calcium leucovorin (LV) on tumor cell incorporation of intraperitoneal (IP) iododeoxyuridine (IudR): flow cytometric analysis. American Society of Clinical Oncology (ASCO), Los Angeles, California, May 1995.
8. **McGonigle KF**, Vasilev SA, Simpson JF. Ovarian pathology in breast cancer patients on Tamoxifen. American Society of Clinical Oncology (ASCO), Los Angeles, California, May 1995.
9. Monk BJ, **McGonigle KF**, Spencer-Smith EL, Vasilev SA. Intestinal peritoneal sling as an adjunct to radical pelvic surgery and pelvic irradiation. Western Association of Gynecologic Oncologists (WAGO), Coeur d'Alene, ID, June 1995.
10. Monk BJ, Fowler JM, Burger RA, **McGonigle KF**, Eddy GL, Montz FJ. The Gore-Tex surgical membrane is effective in preventing pelvic adhesions after radical surgery for ovarian cancer: Results of a controlled,

- randomized, multicenter study. Western Association of Gynecologic Oncologists (WAGO), San Diego, California, May 1996.
11. Morgan R, Dorowshow JH, Newman E, Carrol M, Coluzzi P, Leong L, Shibata S, Chow W, Vasilev S, **McGonigle KF**, Margolin K, Somlo G, Raschko J, Tetef M, et al. High dose VP16, cyclophosphamide, infusional doxorubicin, with autologous bone marrow and peripheral blood stem cell support in patients with ovarian cancer. American Society of Clinical Oncology (ASCO), Los Angeles, California, May 1996.
 12. **McGonigle KF**, Marx HF, Maryon TL, Roy S, Vasilev SA, Simpson JF. The uterine effects of tamoxifen: a prospective study. Society of Gynecologic Oncologists (SGO), Phoenix, Arizona, March 22-26, 1997.
 13. Brewster WR, Grosen E, Kyukendall JL, **McGonigle KF**, DiSaia PJ. Estrogen replacement therapy in breast cancer survivors. Society of Gynecologic Oncologists (SGO), Phoenix, Arizona, March 22-26, 1997.
 14. **McGonigle KF**, Shaw SL, Vasilev SA, Roy S, Simpson JF. Effectiveness of transvaginal ultrasound in detecting endometrial pathology in breast cancer patients receiving tamoxifen. The American College of Obstetricians and Gynecologists (ACOG), Las Vegas, Nevada, April 1997.
 15. Brewster WR, Grosen E, Kuykendall JL, **McGonigle KF**, DiSaia PJ. Estrogen replacement therapy in breast cancer survivors. Western Association of Gynecologic Oncologists (WAGO), Jasper, Alberta, Canada, June 1997.
 16. **McGonigle KF**, Shaw SL, Vasilev SA, Roy S, Simpson JF. Effectiveness of transvaginal ultrasound in detecting endometrial pathology in breast cancer patients receiving tamoxifen. Pacific Coast Obstetrical and Gynecological Society, Coeur d' Alene, Idaho, September 1997.
 17. **McGonigle KF**, Vasilev SA, Maryon T, Simpson JF. Ovarian pathology in breast cancer patients receiving tamoxifen. Western Association of Gynecologic Oncologists (WAGO), Napa Valley, CA, May, 1998.
 18. **McGonigle KF**, Marx HF, Morgan RJ, Maryon TL, Chen E, Roy S, Vasilev SA, Wong, T, Roach L, Wilczynski SP, Simpson JF. Uterine effects of tamoxifen: a prospective study. Western Association of Gynecologic Oncologists (WAGO), 1999.
 19. Reynolds CA, Holschneider CH, Natarjan S, Munro MG, Lemus J, **McGonigle KF**. Toluidine blue for cervical cancer screening: a new use for an old tool. Society of Gynecologic Oncologists (SGO), 2001.

20. Muntz HG, Goff B, **McGonigle KF**, Isaacson C. Significance of Psommoma bodies in screening cervical cytology smears. Pacific Coast OB/GYN Society, 2002.
21. Kuznetsov DD, Govier FE, Kobashi KC, Kozlowski PM, Begley SJ, **McGonigle KF**, Muntz HG. A high vaginal erosion rate identified in sacrocolpopexy patients using silicone mesh. Society of Urodynamics and Female Urology, Scottsdale AZ, 2/27/04.
22. Muntz HG, **McGonigle KF** et al. Phase II study of intraperitoneal topotecan as consolidative therapy in patients with advanced ovarian, fallopian tube and peritoneal cancer. Western Association of Gynecologic Oncologists (WAGO), May, 2004.
23. Muntz HG, **McGonigle KF**, Malpass TW, Robertson MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in patients with advanced ovarian and and primary peritoneal cancer. Martha Rivkin Ovarian Cancer Research Meeting, Seattle, WA, September, 2004.
24. Muntz HG, **McGonigle KF**, Malpass TW, Robertson MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecan as consolidation chemotherapy in patients with advanced ovarian and and primary peritoneal cancer. Society of Gynecologic Oncologists (SGO), March, 2005.
25. Muntz HG, **McGonigle KF**, Jacobs A, Malpass TW. Phase II trial of weekly Docetaxel (Taxotere) as initial chemotherapy for advanced ovarian cancer. Pacific Coast OB/GYN Society. September 2006
26. Muntz HG, **McGonigle KF**, Malpass TM, Robertson MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecan in advanced ovarian cancer. Cancer Investigation 24:39-41; 2006.
27. **McGonigle KF**, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Gray HJ, Malpass TW. Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian or primary peritoneal cancer. Submitted to American Society of Clinical Oncology (ASCO), June 2008.

Work in Progress

Submitted, In Preparation - Journal Articles

1. Muntz HG, **McGonigle KF**, Malpass TW, Robertson MD, Kamarauskiene D, Weiden P. Phase II study of intraperitoneal topotecal as consolidation

- chemotherapy in patients with advanced ovarian and and primary peritoneal cancer. (Submitted, 2007)
2. Muntz HG, **McGonigle KF**, Jacobs A, Malpass TW. Phase II Trial of Weekly Docetaxel (Taxotere) as Initial Chemotherapy for Advanced Ovarian Cancer. (In Preparation)
 3. Malpass TW, Muntz HG, **McGonigle KF**. Intraperitoneal Carboplatin and Taxol Chemotherapy for advanced ovarian cancer. (In Preparation)
 3. Chen Lee-May, **McGonigle KF**. Rapidly progressive cervical cancer during pregnancy: a Case report and review of literature. (In preparation)
 4. Holschneider CH, Reynolds CA, Natarjan S, Munro MG, Lemus J, **McGonigle KF**. Toluidine blue for cervical cancer screening: a new use for an old tool. (In preparation)

Work in Progress-Studies in Progress

Phase II Study of Weekly Topotecan with Bevacizumab in Platinum Resistant Recurrent Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Carcinomas.
PI: Kathryn F. McGonigle

Updated 1/2008